For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Biosimilar therapy is defined as a therapy that is highly similar to approved biopharmaceuticals. They are made by converting biopharmaceuticals made from living cells in the laboratory into large-scale production molecules. This is quite different from the general treatment method, which is identical to the reference small molecule drug. The reason behind this is that it is impossible to make a copy of the same biologic drug.
The Biosimilar Drug market revenue was 16199.84 Million USD in 2022, and will reach 303415.85 Million USD in 2028, with a CAGR of 62.96% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Biosimilar Drug industry, and breaks down according to the type, application, and consumption area of Biosimilar Drug. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Biosimilar Drug in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Biosimilar Drug market covered in Chapter 11:
Novartis
Eli Lilly
Amgen
Changchun High Tech
CP Guojian
Celgen
Biotech
Innovent
Henlius Biotech
In Chapter 3, on the basis of types, the Biosimilar Drug market from 2018 to 2028 is primarily split into:
Tablets
Injection
Others
In Chapter 4, on the basis of applications, the Biosimilar Drug market from 2018 to 2028 covers:
Cardiovascular
Rheumatoid Arthrtis
Tumor
Ankylosing Spondylitis
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2028) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028